ENDRA Life Sciences (NDRA) Accounts Payables (2016 - 2026)

ENDRA Life Sciences has disclosed Accounts Payables across 11 years of filings, most recently posting $701487.0 for Q1 2026.

• In Q1 2026, Accounts Payables rose 59.54% year-over-year to $701487.0; the TTM figure through Mar 2026 stood at $701487.0 (up 59.54% YoY), while the FY2025 annual figure was $621578.0, up 22.29% from the prior year.
• Accounts Payables climbed to $701487.0 in Q1 2026, from $621578.0 in the prior quarter.
• Over the last five years, Accounts Payables for NDRA reached as high as $2.0 million in Q3 2023 and fell as low as $439688.0 in Q1 2025.
• The 5-year median for Accounts Payables is $1.0 million (2024), against an average of $1.1 million.
• Annual changes were most pronounced in 2024 — Accounts Payables sank 68.23% — and 2026, when it jumped 59.54%.
• A 5-year view of Accounts Payables shows it stood at $1.5 million in 2022, then slumped by 53.99% to $700754.0 in 2023, then declined by 27.46% to $508293.0 in 2024, then increased by 22.29% to $621578.0 in 2025, then advanced by 12.86% to $701487.0 in 2026.
• According to Business Quant data, Accounts Payables over the past three periods registered $701487.0, $621578.0, and $671516.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.